Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
carcinoma who are candidates for systemic therapy, based on the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868 Positive opinion also granted for KEYTRUDA plus chemoradiotherap y for the treatment of FIGO 2014 Stage III-IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, based on the Phase 3 KEYNOTE-A18 trial RAHWAY, N.J., September 20, 2024 BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions recommending approval of KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, for two indications in gynecologic cancers. The first opinion recommends the approval of KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are cand
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck Loses Around $32B in 3 Months: Time to Sell the Stock? [Yahoo! Finance]Yahoo! Finance
- Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic CancersBusiness Wire
- Merck's Keytruda Obtains its First FDA Approval for Mesothelioma [Yahoo! Finance]Yahoo! Finance
- Korean Biotech's Shares Quadruple In Seven Months, Becomes Kosdaq's Biggest Stock [Forbes]Forbes
- SKB264 Innovative Cancer Antibody Drug Conjugate Clinical Trials Efficacy Insight [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 7/30/24 - Beat
MRK
Sec Filings
- 8/6/24 - Form 4
- 8/5/24 - Form 10-Q
- 7/30/24 - Form 8-K
- MRK's page on the SEC website